Positive News SentimentPositive NewsNASDAQ:NBTX Nanobiotix (NBTX) Stock Price, News & Analysis $5.16 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.16▼$5.1650-Day Range$4.16▼$7.2352-Week Range$4.14▼$11.00Volume277 shsAverage Volume3,844 shsMarket Capitalization$243.19 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Nanobiotix alerts: Email Address Nanobiotix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside113.2% Upside$11.00 Price TargetShort InterestHealthy0.11% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.82) to ($0.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.31 out of 5 starsMedical Sector576th out of 936 stocksPharmaceutical Preparations Industry261st out of 436 stocks 3.5 Analyst's Opinion Consensus RatingNanobiotix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNanobiotix has received no research coverage in the past 90 days.Read more about Nanobiotix's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.11% of the outstanding shares of Nanobiotix have been sold short.Short Interest Ratio / Days to CoverNanobiotix has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Nanobiotix has recently decreased by 9.79%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNanobiotix does not currently pay a dividend.Dividend GrowthNanobiotix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NBTX. Previous Next 2.7 News and Social Media Coverage News SentimentNanobiotix has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nanobiotix this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nanobiotix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.45% of the stock of Nanobiotix is held by insiders.Percentage Held by InstitutionsOnly 38.81% of the stock of Nanobiotix is held by institutions.Read more about Nanobiotix's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nanobiotix are expected to grow in the coming year, from ($0.82) to ($0.44) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Nanobiotix Stock (NASDAQ:NBTX)Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Read More NBTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBTX Stock News HeadlinesJune 12, 2024 | globenewswire.comNANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024June 2, 2024 | globenewswire.comNanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 TherapyJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 28, 2024 | globenewswire.comNANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference CallMay 23, 2024 | globenewswire.comNANOBIOTIX to Present at the Jefferies Global Healthcare ConferenceMay 22, 2024 | finanznachrichten.deNanobiotix S.A.: Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term GrowthMay 22, 2024 | globenewswire.comNANOBIOTIX Provides First Quarter 2024 Operational and Financial UpdateMay 21, 2024 | globenewswire.comNanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term GrowthJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 15, 2024 | globenewswire.comNANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024May 14, 2024 | globenewswire.comNANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung CancerApril 29, 2024 | seekingalpha.comNanobiotix S.A. (NBTX) Q4 2023 Earnings Call TranscriptApril 26, 2024 | benzinga.comNanobiotix Stock (NASDAQ:NBTX), Earnings Estimates, EPS, and RevenueApril 24, 2024 | globenewswire.comNANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial ResultsApril 17, 2024 | globenewswire.comNANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024April 2, 2024 | globenewswire.comNanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-IrradiationMarch 6, 2024 | globenewswire.comNanobiotix to Present at Upcoming Investor Conferences in MarchJanuary 31, 2024 | finance.yahoo.comNanobiotix to Present at the Guggenheim 6th Annual Biotechnology ConferenceSee More Headlines Receive NBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NBTX CUSIPN/A CIK1760854 Webwww.nanobiotix.com Phone33-1-40-26-04-70FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+113.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.75 Quick Ratio1.75 Sales & Book Value Annual Sales$39.18 million Price / Sales6.21 Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-129.00Miscellaneous Outstanding Shares47,130,000Free Float45,507,000Market Cap$243.19 million OptionableNot Optionable Beta0.26 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesMr. Laurent Levy Ph.D. (Age 51)Co-Founder, President of the Executive Board & CEO Comp: $774.87kMr. Bart Van Rhijn (Age 51)CFO & Member of Executive Board Comp: $682.2kMs. Anne-Juliette Hermant M.A. (Age 50)Chief People Officer & Member of Executive Board Comp: $385.23kDr. Louis Kayitalire M.D. (Age 66)Chief Medical Officer Comp: $543.6kMr. Earl J. Bergey Ph.d. (Age 69)Co-Founder Mr. Craig West CFASenior Vice President of Investor RelationsMr. Brandon OwensVP of Strategic Marketing & Corporate CommunicationMr. Patrick Tricoli M.B.A.Pharm.D., Global Head of Business DevelopmentMs. Margaret GalluzziVP & Global Head of Clinical OperationsMr. Ventzislav Vassilev M.D.VP & Global Head of Safety VigilanceMore ExecutivesKey CompetitorsOPKO HealthNASDAQ:OPKARS PharmaceuticalsNASDAQ:SPRYPraxis Precision MedicinesNASDAQ:PRAXCentessa PharmaceuticalsNASDAQ:CNTAPacira BioSciencesNASDAQ:PCRXView All Competitors NBTX Stock Analysis - Frequently Asked Questions How have NBTX shares performed this year? Nanobiotix's stock was trading at $7.28 at the start of the year. Since then, NBTX stock has decreased by 29.1% and is now trading at $5.16. View the best growth stocks for 2024 here. When did Nanobiotix IPO? Nanobiotix (NBTX) raised $95 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 6,500,000 shares at $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont served as the underwriters for the IPO. How do I buy shares of Nanobiotix? Shares of NBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NBTX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.